Finan et al. (55) found that the hybrid thyroid hormone-glucagon 147 complex can improve the degree of liver steatosis in NAFLD patients without adverse reactions in the skeletal muscle and cardiovascular system. This evidence concerns the gene GCG and Hepatic steatosis.